Related Experiment Videos
Botulinum toxin for spasmodic dysphonia.
1Department of Rehabilitation Medicine, University of Washington School of Medicine, c/o Gail Wise (Mail Stop 117-RCS), VA Puget Sound Health Care System, 1660 S. Columbian Way, Seattle, WA 98108, USA.
Physical Medicine and Rehabilitation Clinics of North America
|October 29, 2003
Summary
Botulinum toxin injections effectively manage adductor spasmodic dysphonia (SD), improving vocal function for most patients. However, results are less consistent for abductor SD, highlighting the need for a multidisciplinary team approach.
Area of Science:
- Neurology
- Otolaryngology
- Speech-Language Pathology
Background:
- Spasmodic dysphonia (SD) is a voice disorder affecting vocal fold muscle control.
- Botulinum toxin is a primary treatment for SD, particularly adductor type.
- Treatment outcomes vary between adductor and abductor SD subtypes.
Purpose of the Study:
- To review the efficacy of botulinum toxin in managing spasmodic dysphonia.
- To emphasize the importance of a comprehensive management strategy for SD.
- To define the role of physiatrists in the multidisciplinary SD care team.
Main Methods:
- Review of current literature on botulinum toxin treatment for SD.
- Analysis of treatment outcomes based on SD subtype (adductor vs. abductor).
- Discussion of the collaborative care model involving various medical specialists.
Main Results:
- Botulinum toxin injections yield satisfactory vocal function in the majority of adductor SD patients.
- Treatment results with botulinum toxin are less favorable for patients with abductor SD.
- A team-based approach is recommended for optimal SD management.
Conclusions:
- Botulinum toxin is an established and effective treatment for adductor SD.
- Further research or alternative strategies may be needed for abductor SD.
- Physiatrists experienced in electromyography (EMG) and botulinum toxin administration are key members of the SD management team.